Autobio(SH:603658) Huachuang Securities·2025-11-21 02:15Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 53 yuan [2][8]. Core Insights - The company's revenue for the first three quarters of 2025 was 3.127 billion yuan, a decrease of 7.48% year-on-year, with a net profit attributable to shareholders of 860 million yuan, down 10.11% [2][8]. - The third quarter of 2025 saw a revenue of 1.067 billion yuan, a decline of 9.04% year-on-year, and a net profit of 289 million yuan, down 14.30% [2][8]. - The decline in revenue and profit is attributed to factors such as domestic market procurement and price reductions in testing projects [8]. - The company has been enhancing its IVD product system, with multiple new products approved since Q3 2025, expanding its offerings to over 300 testing projects [8]. Financial Performance Summary - Total revenue projections for 2024A, 2025E, 2026E, and 2027E are 4.471 billion, 4.235 billion, 4.675 billion, and 5.386 billion yuan respectively, with year-on-year growth rates of 0.6%, -5.3%, 10.4%, and 15.2% [4][9]. - Net profit attributable to shareholders is projected to be 1.194 billion, 1.177 billion, 1.370 billion, and 1.590 billion yuan for the same years, with growth rates of -1.9%, -1.5%, 16.4%, and 16.1% [4][9]. - The earnings per share (EPS) are expected to be 2.09, 2.06, 2.40, and 2.78 yuan for 2024A, 2025E, 2026E, and 2027E respectively [4][9]. Product Development and Market Position - The company has been actively improving its IVD product lineup, with significant product approvals enhancing its market position [8]. - By the end of 2025, the number of immunobiochemical product line reagents is expected to reach 338 [8].